35th European Cystic Fibrosis Conference The Convention Centre, Dublin, Ireland, 6-9 June 2012 More than 2400 delegates attended the 35th European Cystic Fibrosis Conference held in Dublin between 6 and 9 June 2012. More than 525 abstracts were presented at the conference. There were 30 symposia with four speakers at each, in addition to numerous workshops where researchers had the opportunity to present their work into scientific, clinical and psychological aspects of cystic fibrosis care. Keynote speakers provided state of the art lectures in two plenary sessions. This report highlights two important areas in the field of molecular genetics and the need for new and validated clinical trial end points.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/ers.12.52 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Studies showed significant physical improvement after starting elexacaftor/tezacaftor/ivacaftor (ETI). However, some patients reported new mental health symptoms.
Aim: This study explores the impact of ETI on end-stage cystic fibrosis patients, focusing on mental health.
Metabolomic profiling of saliva from cystic fibrosis patients.
Sci Rep
January 2025
CEINGE-Biotecnologie avanzate Franco Salvatore, Via G. Salvatore 486, Naples, 80145, Italy.
The development of targeted therapies that correct the effect of mutations in patients with cystic fibrosis (CF) and the relevant heterogeneity of the clinical expression of the disease require biomarkers correlated to the severity of the disease useful for monitoring the therapeutic effects. We applied a targeted metabolomic approach by LC-MS/MS on saliva samples from 70 adult CF patients and 63 age/sex-matched controls to investigate alterations in metabolic pathways related to pancreatic insufficiency (PI), Pseudomonas aeruginosa (PA) colonization, CF liver disease (CFLD), and CF related diabetes (CFRD). Sixty salivary metabolites were differentially expressed, with 11 being less abundant and 49 more abundant in CF patients.
View Article and Find Full Text PDFA 3-year-old girl treated with intravenous chemotherapy for bilateral retinoblastoma (RB) and a standard technique of intravitreal topotecan for vitreous seeds in the left eye developed a conjunctival nodule at the injection site. Ultrasound biomicroscopy showed normal underlying sclera and ciliary body. Fundus examination of the left eye showed partly calcified vitreous seeds.
View Article and Find Full Text PDFModifies Chronic Airway Infection Risk in Cystic Fibrosis.
Ann Am Thorac Soc
January 2025
University of Washington, Genomic Sciences, Seattle, Washington, United States.
Rationale: Chronic () airway infection is common and a key contributor to diminished lung function and early mortality in persons with cystic fibrosis (PwCF). Risk factors for chronic among PwCF include cystic fibrosis transmembrane conductance regulator genotype, genetic modifiers, and environmental factors. Intensive antibiotic therapy and highly effective modulators do not eradicate in most adolescents and adults with cystic fibrosis.
View Article and Find Full Text PDFTwo different diseases in two adolescent girls with the same clinic: Allergic bronchopulmonary aspergillosis.
Tuberk Toraks
December 2024
Division of Pediatric Pulmonology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Türkiye.
Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction observed in asthma as well as cystic fibrosis (CF) patients due to the colonization of the airways by Aspergillus fumigatus. While ABPA is most commonly observed in CF patients (2-9%), it is seen at a rate of 1-2% in patients diagnosed with asthma. ABPA is mostly seen in steroid dependent adult asthma patients and has rarely been reported in pediatric asthma patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!